200 related articles for article (PubMed ID: 30336686)
1. Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia.
Wu X; Gong C; Weinstock J; Cheng J; Hu S; Venners SA; Hsu YH; Wu S; Zha X; Jiang S; Li Y; Pan F; Xu X
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):240S-247S. PubMed ID: 30336686
[TBL] [Abstract][Full Text] [Related]
2. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
3. Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.
Kaewboonlert N; Thitisopee W; Sirintronsopon W; Porntadavity S; Jeenduang N
J Clin Pharm Ther; 2018 Oct; 43(5):647-655. PubMed ID: 29575099
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients.
Yang GP; Yuan H; Tang B; Zhang W; Wang LS; Huang ZJ; Ou-Yang DS; Zhang GX; Zhou HH
Acta Pharmacol Sin; 2010 Mar; 31(3):382-6. PubMed ID: 20140004
[TBL] [Abstract][Full Text] [Related]
5. Influence of
Mladenovska K; Grapci AD; Vavlukis M; Kapedanovska A; Eftimov A; Geshkovska NM; Nebija D; Dimovski AJ
Pharmazie; 2017 May; 72(5):288-295. PubMed ID: 29441875
[TBL] [Abstract][Full Text] [Related]
6. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
Rodrigues AC; Perin PM; Purim SG; Silbiger VN; Genvigir FD; Willrich MA; Arazi SS; Luchessi AD; Hirata MH; Bernik MM; Dorea EL; Santos C; Faludi AA; Bertolami MC; Salas A; Freire A; Lareu MV; Phillips C; Porras-Hurtado L; Fondevila M; Carracedo A; Hirata RD
Int J Mol Sci; 2011; 12(9):5815-27. PubMed ID: 22016628
[TBL] [Abstract][Full Text] [Related]
8. SLCO1B1 gene variability influences lipid-lowering efficacy on simvastatin therapy in Southern Brazilians.
Sortica VA; Fiegenbaum M; Lima LO; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
Clin Chem Lab Med; 2012 Mar; 50(3):441-8. PubMed ID: 22505549
[TBL] [Abstract][Full Text] [Related]
9. Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics.
Wagner JB; Abdel-Rahman S; Van Haandel L; Gaedigk A; Gaedigk R; Raghuveer G; Kauffman R; Leeder JS
J Clin Pharmacol; 2018 Jun; 58(6):823-833. PubMed ID: 29469964
[TBL] [Abstract][Full Text] [Related]
10. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
11. The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study.
Zakria M; Hussain A; Ahmad N; Ahmed N; Rauf MA; Siraj S
Eur Rev Med Pharmacol Sci; 2023 May; 27(10):4708-4717. PubMed ID: 37259755
[TBL] [Abstract][Full Text] [Related]
12. Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia.
Sivkov A; Chernus N; Gorenkov R; Sivkov S; Sivkova S; Savina T
Lipids Health Dis; 2021 Nov; 20(1):157. PubMed ID: 34749751
[TBL] [Abstract][Full Text] [Related]
13. Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia.
Hu M; Mak VW; Tomlinson B
Pharmacogenet Genomics; 2012 Nov; 22(11):803-6. PubMed ID: 22668755
[TBL] [Abstract][Full Text] [Related]
14. SLCO1B1 polymorphism and oral antidiabetic drugs.
Kalliokoski A; Neuvonen PJ; Niemi M
Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):775-81. PubMed ID: 20406215
[TBL] [Abstract][Full Text] [Related]
15. Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins.
Dou Y; Zhu X; Wang Q; Tian X; Cheng J; Zhang E
Ann Lab Med; 2015 May; 35(3):329-35. PubMed ID: 25932441
[TBL] [Abstract][Full Text] [Related]
16. Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations.
Nagy A; Sipeky C; Szalai R; Melegh BI; Matyas P; Ganczer A; Toth K; Melegh B
BMC Genet; 2015 Sep; 16():108. PubMed ID: 26334733
[TBL] [Abstract][Full Text] [Related]
17. Association of SLCO1B1 Polymorphisms and Atorvastatin Safety and Efficacy: A Meta-analysis.
Du Y; Wang S; Chen Z; Sun S; Zhao Z; Li X
Curr Pharm Des; 2018; 24(34):4044-4050. PubMed ID: 30569848
[TBL] [Abstract][Full Text] [Related]
18. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
[TBL] [Abstract][Full Text] [Related]
19. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
Pasanen MK; Backman JT; Neuvonen PJ; Niemi M
Eur J Clin Pharmacol; 2006 Jun; 62(6):409-15. PubMed ID: 16758257
[TBL] [Abstract][Full Text] [Related]
20. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
